Introduction/Background Critical complication during chemotherapy is febrile neutropenia.. Granulocyte-colony-stimulating factor(G-CSF) is used to prevent febrile neutropenia associated with myelosuppression. Pegfilgrastim, a pegylated form of filgrastim, has an increased half-life. Pegteograstim is novel recombination human G-CSF of another form of pegylated filgrastim.We undertook investigation to evaluate efficacy and safety of pegteograstim and pegfilgrastim women with ovarian carcinoma that are treated with paclitaxel/carboplatin.

Methodology After chemotherapy minimum 24 hours, pegteograstim or pegfilgrastim was given a single subcutaneous injection of 6 mg during each chemotherapy cycle. We evaluated to ANC (absolute neutrophil count) change and febrile neutropenia incidence.

Results There were 30 of pegteograstim cases and 12 pegfilgrastim.Median ANC between pegteostim were 2960.pegfilgrastim was 2396.After pegteograstim, ANC was elevated till 13847 from 2960 (difference was 10,887)in case of pegteograstim. In pegfilgrastim, ANC increased to 12933 (difference was 10537).There was no febrile neutropenia in both cases. Safety profiles of two groups did not differ significantly.

Conclusion We conclude Pegteograstim and pegfilgrastim have similar efficacy and safety profile in the reduction of chemotherapy-induced neutropenia in the ovary cancer patients who were undergoing chemotherapy.

Disclosures NO COI.